FDA places clinical hold on Sarepta Therapeutics' treatment for Duchenne muscular dystrophy. FedEx issues upbeat guidance for its full fiscal year, projecting a rise in adjusted earnings. FedEx reports mixed results for its recently completed fiscal fourth quarter, with $6.87 inadjusted earnings per share.

Smith & Wesson's fiscal fourth-quarter report showed a year over year decline in revenue and gross margin. The company, which has a market cap of roughly $650 million, hiked its quarterly divided to 10 cents per share. Sarepta said there was a "serious adverse event" in one of the studies for the treatment.
Posted by
Tap to copy the Short Url to this post: 
One-Stop Business News. Free to Use →